Chinese Scientists Develop FACE Platform to Overcome CAR-T Therapy Resistance in Leukemia
核心洞察
Chinese researchers have developed FACE (搜索) (ferritin aggregation cell engager), a molecular bridge that enhances CAR-T cell therapy effectiveness by connecting immune cells to leukemia cells through the CD71 (搜索) protein.
The platform achieved 100% survival rates in mouse models even when cancer cells lost their surface markers, addressing a major cause of treatment failure in CAR-T therapy.
FACE (搜索) can be integrated into existing CAR-T manufacturing workflows without genetic modifications and uses FDA-approved materials, potentially accelerating clinical translation.
Chinese scientists have developed a breakthrough platform that could transform CAR-T cell therapy for leukemia patients by preventing cancer cells from evading treatment. The innovative approach, published in the journal Cell, uses a molecular "bridge" called FACE (搜索) (ferritin aggregation cell engager) to maintain the connection between engineered immune cells and cancer cells, even when leukemia attempts to hide from detection.
Addressing CAR-T Therapy's Major Challenge
CAR-T cell therapy, which involves extracting a patient's T cells, genetically modifying them to target cancer, and reinfusing them, has shown remarkable success in treating certain blood cancers. However, more than half of patients experience relapse because cancer cells can alter or lose the surface markers that CAR-T cells are programmed to recognize.
"In many patients, however, the cancer comes back after the therapy. This happens because cancer cells can hide. They remove the marker on their surface that the CAR T cells are looking for. Once hidden, CAR T cells cannot find them," explained the research team from the Institute of Process Engineering (IPE) at the Chinese Academy of Sciences.
Traditional solutions require returning to the laboratory to genetically redesign the T cells, a process that is expensive, time-consuming, and technically challenging.
The FACE Platform Innovation
The researchers discovered that both leukemia cells and CAR-T cells express high levels of CD71 (搜索), a protein involved in iron transport, across different leukemia types and disease stages. This observation led to the development of FACE (搜索), created from ferritin, a natural protein that binds to CD71.
"FACE (搜索) serves as a tiny bridge or a piece of strong glue. Even when leukemia cells try to hide, FACE helps the CAR T cells hold on and do their job," said Wei Wei, one of the lead researchers from the IPE.
The platform works by attaching to CAR-T cells during a simple 30-minute co-incubation process. Once infused into patients, FACE (搜索) also binds to CD71 (搜索) on leukemia cells, creating a molecular bridge that enhances the interaction between the two cell types.
Remarkable Preclinical Results
In laboratory studies using mouse models with patient-derived leukemia cells, the FACE (搜索)-enhanced CAR-T therapy demonstrated exceptional efficacy. Even when antigen levels dropped below 10 percent of normal—conditions that render leukemia cells nearly invisible to conventional CAR-T cells—the FACE-enabled therapy achieved a 100 percent survival rate in all tested mice.
The platform also showed impressive efficiency, achieving the same therapeutic effect as conventional CAR-T therapy using only one-fifth of the typical cell dose while significantly reducing side effects.
Enhanced Drug Delivery Capabilities
Taking advantage of FACE (搜索)'s cage-like structure, the researchers developed a drug-loaded version that delivers chemotherapy directly to leukemia cells. This combination of CAR-T therapy and targeted chemotherapy further enhances therapeutic effectiveness, particularly against cancer cells that have lost their target antigens.
Clinical Translation Potential
The FACE (搜索) platform offers several advantages for clinical implementation. "Our FACE platform is composed of an endogenous protein and polymer derivatives approved by the United States Food and Drug Administration, and it can be prepared through a simple and scalable process," Wei noted.
Importantly, the platform can be seamlessly integrated into existing CAR-T cell manufacturing workflows without requiring additional genetic engineering, potentially accelerating its path to clinical use.
Ma Guanghui, an academician of the Chinese Academy of Sciences and study co-author, emphasized the platform's broad applicability: "The FACE (搜索) platform was validated in multiple mouse models and human patient samples, demonstrating its broad applicability across multiple leukemia subtypes and treatment-resistant settings."
AI-Assisted Development
To support clinical translation, the research team established an efficacy database and developed an AI-assisted predictive framework capable of accurately forecasting FACE (搜索)-mediated enhancement, potentially helping optimize treatment protocols for individual patients.
Peer reviewers at Cell described the findings as "a promising translational approach" to improving responsiveness against leukemia and other blood cancers, highlighting the strategy's potential to combat the variability of leukemia antigens without requiring additional genetic modifications.